CDT on Nasdaq
CDT Equity Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development expenses | $5.1M | $3.4M |
| General and administrative expenses | $31.7M | $12.0M |
| Total operating costs and expenses | $36.8M | $15.4M |
| Operating loss | -$36.8M | -$15.4M |
| Other expense, net | -$2.2M | -$890.0K |
| Interest income | $28.0K | $13.0K |
| Interest expense, net | -$319.0K | -$1.5M |
| Total other expense, net | -$2.5M | -$2.4M |
| Net loss | -$39.2M | -$17.8M |
| Basic net loss per share | -$1,177.89 | -$61,598.62 |
| Diluted net loss per share | -$1,177.89 | -$61,598.62 |
| Basic weighted-average common shares outstanding | 33.3K shares | 289 shares |
| Diluted weighted-average common shares outstanding | 33.3K shares | 289 shares |
| Foreign currency translation adjustment | -$430.0K | $3.0K |
| Total comprehensive loss | -$39.7M | -$17.8M |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2024-02-29 |
|---|---|---|---|
| Cash and cash equivalents | $1.5M | $554.0K | |
| Prepaid R&D services- related party (see Note 10 and Note 16) | $881.0K | $380.0K | |
| Prepaid R&D services | $166.0K | ||
| Prepaid expenses and other current assets | $1.8M | $1.8M | |
| Total current assets | $4.4M | $2.7M | |
| Operating lease right-of-use assets, net | $142.0K | $263.0K | $400.0K |
| Equipment and clinical assets, net | $269.0K | $40.0K | |
| Prepaid expenses and other long-term assets | $860.0K | $1.2M | |
| Total assets | $5.7M | $4.2M | |
| Accounts payable | $1.9M | $1.4M | |
| Accrued expenses and other current liabilities | $538.0K | $2.0M | |
| Accrued litigation liability | $9.6M | ||
| Operating lease liability, current portion | $115.0K | $119.0K | $200.0K |
| Convertible promissory note payable | $800.0K | ||
| Total current liabilities | $12.8M | $10.7M | |
| Operating lease liability, non-current portion | $107.0K | $200.0K | |
| Derivative warrant liability | $138.0K | ||
| Total liabilities | $12.8M | $11.0M | |
| Additional paid-in capital | $61.2M | $21.9M | |
| Accumulated deficit | -$68.3M | -$29.1M | |
| Accumulated other comprehensive income (loss) | -$16.0K | $414.0K | |
| Total stockholders equity (deficit) | -$7.2M | -$6.8M | |
| Total liabilities and stockholders equity (deficit) | $5.7M | $4.2M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 250.0M shares | 250.0M shares | |
| Common stock, shares issued | 92.1K shares | 461 shares | |
| Common stock, shares outstanding | 92.1K shares | 461 shares | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$39.2M | -$17.8M |
| Compensation expense recognized for the issuance of shares and warrants in connection with the sale of a previously controlled subsidiary | $7.0M | |
| Gain on debt extinguishment, net | -$278.0K | |
| Loss on debt extinguishment, net | $707.0K | |
| Realized gain on short-term investments | -$8.0K | |
| Loss on disposal of crypto holdings | $403.0K | |
| Gain on waiver of accrued interest | -$371.0K | |
| Unrealized foreign exchange gain / loss | -$16.0K | $13.0K |
| Loss (gain) on change in fair value of convertible notes payable | $2.7M | -$2.0M |
| Gain on change in fair value of warrants | -$138.0K | -$221.0K |
| Loss on issuance of warrants | $2.7M | |
| Non-cash lease expense | $125.0K | $89.0K |
| Stock-based compensation expense | $2.2M | $1.6M |
| Issuance of common stock for licensing right | $1.6M | |
| Non-cash interest expense | $253.0K | $536.0K |
| Depreciation expense | $21.0K | $10.0K |
| Amortization of prepaid directors and officers insurance | $1.4M | $1.7M |
| Amortization expense | $2.4M | $447.0K |
| Issuance of common stock for services | $1.2M | |
| Issuance of common stock for services - related party | $2.1M | |
| Amortization of debt discount | $929.0K | |
| Gain (loss) on issuance of common stock for services | -$70.0K | $202.0K |
| Prepaid expenses and other current assets | -$4.1M | -$2.3M |
| Accounts payable | $434.0K | $1.2M |
| Accrued expenses and other current liabilities | -$1.1M | $1.0M |
| Accrued litigation liability | $9.6M | |
| Lease liability | -$125.0K | -$124.0K |
| Net cash used in operating activities | -$15.6M | -$9.7M |
| Purchase of digital assets | -$2.0M | |
| Proceeds from disposal of digital assets | $1.6M | |
| Purchase of equipment and clinical assets | -$405.0K | -$51.0K |
| Purchases of short-term investments | -$490.0K | |
| Proceeds from the sale of short-term investments | $498.0K | |
| Net cash flows used in investing activities | -$808.0K | -$43.0K |
| Proceeds from the issuance of notes payable related parties | $3.2M | |
| Proceeds from issuance of common shares related to ATM program | $19.7M | $3.3M |
| Exercise of warrants | $176.0K | |
| Repayment of notes payable | -$158.0K | -$776.0K |
| Proceeds from issuance of warrants | $113.0K | |
| Repayment of notes payable - related parties | -$425.0K | |
| Repayment of convertible notes payable - related parties | -$927.0K | |
| Repayment of convertible notes payable | -$661.0K | |
| Purchases of treasury stock | -$106.0K | |
| Net cash flows provided by financing activities | $17.4M | $6.1M |
| Net change in cash and cash equivalents before effect of exchange rate changes | $1.1M | -$3.7M |
| Effect of exchange rate changes on cash and cash equivalents | -$104.0K | -$16.0K |
| Net change in cash | $955.0K | -$3.7M |
| Right of Use Asset obtained in exchange for Operating Lease Liabilities | $352.0K | |
| Correction of immaterial error related to franchise tax expense | $144.0K | |
| Issuance of Common Stock upon exercise of conversion option | $7.1M | $92.0K |
| Issuance of Common Stock in exchange for debt extension | $489.0K | |
| Shares cancelled | -$106.0K | |
| Conversion of deferred commission payable to convertible promissory note | $5.4M | |
| Cash paid for interest | $80.0K |
Former names
Recent filings
- Oct 13, 20268-K
- Oct 13, 2026424B3
- Oct 8, 2026SCHEDULE 13G/A
- Oct 7, 2026SCHEDULE 13G/A
- Oct 7, 2026SCHEDULE 13G/A
- Oct 7, 2026SCHEDULE 13G
- Oct 2, 2026424B3
- Sep 25, 20268-K
- Sep 18, 2026424B3
- Sep 18, 20268-K
- Sep 18, 2026424B3
- Sep 17, 2026EFFECT
- Sep 9, 2026SCHEDULE 13G
- Sep 8, 2026S-1
- Sep 4, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCDT Equity Inc. filings on SEC EDGAR
- 2SEC EDGARCDT Equity Inc. filings on SEC EDGAR
- 3SEC EDGARCDT Equity Inc. 10-K for fiscal 2022
- 4SEC EDGARCDT Equity Inc. 10-K for fiscal 2023
- 5SEC EDGARCDT Equity Inc. 10-K for fiscal 2024
- 6SEC EDGARCDT Equity Inc. 10-Q for fiscal 2026
- 7SEC EDGARCDT Equity Inc. 10-Q for fiscal 2026
- 8SEC EDGARCDT Equity Inc. 10-K for fiscal 2021